Volume 89 Issue 43 | p. 18 | Concentrates
Issue Date: October 24, 2011

Abbott Will Split Into Two Companies

Department: Business
Keywords: kinase, Beijing, oncology

Abandoning its structure as a diversified health care company, Abbott Laboratories will split into separate medical products and research-based drug companies. The medical products company will have annual sales of about $22 billion. It will include Abbott’s nutritional products, diagnostics, medical devices, and branded-generics businesses and will retain the Abbott name. The pharmaceutical firm, to be named later, will have annual sales of about $18 billion. Leading products will include Humira, Lupron, Synagis, Kaletra, Creon, and Synthroid.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment